Futura Medical, the AIM-quoted developer of the Eroxon erectile dysfunction gel, appeared among the most volatile UK stocks on 23 September 2026. A deeply discounted fundraise, a formal sale process and a reset of its US commercial model have put the sub-penny shares under the spotlight.
Futura Medical plc (LSE:FUM) featured among the most volatile UK stocks on 23 September 2026, the same day shareholders were due to vote on its latest fundraising at a general meeting. The company is quoted on AIM; this article uses the FTSE AIM All-Share as a market backdrop rather than claiming verified index membership.
Futura develops and commercialises sexual health products, led by Eroxon, a topical gel for erectile dysfunction. In early September it combined a placing priced at a 37.6% discount with the launch of a formal sale process, putting the company into a Takeover Code offer period. That mix of dilution and possible corporate activity is a classic recipe for sharp share price swings.
Why Futura Medical (FUM) Is in Focus
The trigger was the announcement on 3 September 2026. Futura said it would raise about £1.6m at 0.2p per share, plus a retail offer, and launch a formal sale process and wider M&A process to explore Options ranging from asset sales and licensing to a sale of the company. The board said it believes the current market valuation does not adequately reflect the strategic value of its portfolio.
Interim results two days earlier had disclosed a cash runway only to around October 2026 without new funding, and the directors flagged a material uncertainty over going concern. The raise, the company said, extends the runway into February 2027.
What Does Futura Medical Do?
Futura's lead product, Eroxon (developed as MED3000), is a clinically tested gel for erectile dysfunction available without prescription in markets including the US, Europe, Mexico and the Middle East. The company says in-market sales have shown greater stability over the four quarters to June 2026, and that patents granted in China in December 2025 and the US in March 2026 extend protection to 2040.
The pipeline includes Eroxon Intense, a stronger formulation, and WSD4000, a product for female sexual health. Futura is moving from a pure licensing model towards what it calls a hybrid R&D and commercial model, aiming for more control over positioning and better margins.
What Has Been Happening Recently?
On 29 June 2026 Futura ended its US arrangement with Haleon, which paid a US$1.9m termination fee, and appointed Market Performance Group (MPG) as its new US partner. MPG took commercial control on 1 September. On 30 June the company reported what it called highly positive data from WSD4000 studies, and on 31 July it announced EU market launch clearance for Eroxon Intense.
Interim results followed on 1 September, then the fundraise and sale process on 3 September. On 7 September Futura said its retail offer was significantly oversubscribed and had been increased to £200,000, bringing the total raise to about £1.8m. On 10 September it announced that non-executive director Roy Davis would step down on 20 October 2026. Since the Offer Period began, a stream of Form 8 dealing disclosures has been published, as the Takeover Code requires.
What Are the Numbers Saying?
For the six months to 30 June 2026, Revenue was £1.62m (H1 2025: £1.00m), but £1.40m of that was the Haleon settlement; underlying revenue, mainly US royalties, was £0.21m. The operating loss narrowed to £1.20m from £6.72m, and pre-exceptional administrative expenses fell 17% to £2.19m. Cash was £1.24m at 30 June and an unaudited £1.06m at 31 July.
The fundraise was priced at 0.2p against a 0.32p closing price on 2 September. It involves about 876 million new shares, around 60.1% of the enlarged share capital, lifting shares in issue from 581.3 million to about 1.46 billion. The company's broker is also due to receive 204.9 million warrants exercisable at 0.2p.
Why Is the Share Price Attracting Attention?
The facts: the shares trade below one penny, the company has just issued stock at a steep discount, and a formal sale process means potential bidders can emerge. Non-binding offers are invited by 2 October 2026, although the company has stressed there can be no certainty that any offer will be made or on what terms.
One possible interpretation of the Volatility is that investors are weighing two very different outcomes: further dilution if no acceptable deal appears, or a transaction that values the pipeline above the current market price. Some investors may view the board's estimates of peak annual consumer sales above US$400m for WSD4000 and above US$250m for the Eroxon products as supportive; others may focus on the limited cash position. Both readings are management-led and should be treated with caution.
How Does the FTSE AIM All-Share Context Matter?
Small healthcare companies on AIM have often found Equity funding expensive, and discounted placings accompanied by strategic reviews are a familiar pattern across the FTSE AIM All-Share. That backdrop may help explain why the market reacted to Futura's funding need, but there is no evidence that broad index movements drove the stock. Its recent price action appears to reflect company-specific announcements, including the offer period.
What Could Investors Watch Next?
Several dated items may influence sentiment:
- General meeting outcome: the 23 September vote on the equity fundraising resolutions, with admission of the remaining new shares expected on 25 September 2026.
- Formal sale process: the 2 October 2026 deadline for non-binding offers and any subsequent Takeover Code announcements.
- US relaunch: early sales data from MPG, which took over US commercial control on 1 September.
- Eroxon Intense: FDA clearance, which the company anticipates in the fourth quarter of 2026.
- Board change: Roy Davis's departure on 20 October, after which the board will have four members.
The Bottom Line
Futura Medical's appearance among the most volatile UK stocks follows a busy September: interim results with a Going Concern warning, a raise of about £1.8m at a 37.6% discount, and a formal sale process that places the company in an offer period. Underlying revenue remains small, while the new US partnership, Patent protection to 2040 and the WSD4000 data give the board a case to put to potential partners or bidders. The key issues now are whether the sale process produces credible offers by early October, how the US relaunch performs, and how long the extended cash runway lasts.






Please wait processing your request...